Gilead secured US approval for bulevirtide (Hepcludex), restarting a program the FDA rejected about four years earlier over manufacturing and distribution concerns. The approval reopens a commercial and clinical pathway for chronic hepatitis D, a disease with limited options and high unmet need. The latest decision effectively resolves the prior regulatory hold while Gilead’s supply chain and quality systems remain under scrutiny as the product scales.